These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21034788)

  • 21. Activity of muscarinic, galanin and cannabinoid receptors in the prodromal and advanced stages in the triple transgenic mice model of Alzheimer's disease.
    Manuel I; Lombardero L; LaFerla FM; Giménez-Llort L; Rodríguez-Puertas R
    Neuroscience; 2016 Aug; 329():284-93. PubMed ID: 27223629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psychosis of Alzheimer's disease is associated with elevated muscarinic M2 binding in the cortex.
    Lai MK; Lai OF; Keene J; Esiri MM; Francis PT; Hope T; Chen CP
    Neurology; 2001 Sep; 57(5):805-11. PubMed ID: 11552008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia.
    Zavitsanou K; Garrick T; Huang XF
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):355-60. PubMed ID: 14751433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes of several brain receptor complexes in the cerebral cortex of patients with Alzheimer disease: probable new potential pharmaceutical targets.
    Falsafi SK; Roßner S; Ghafari M; Groessl M; Morawski M; Gerner C; Lubec G
    Amino Acids; 2014 Jan; 46(1):223-33. PubMed ID: 24292102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Positron emission tomography shows elevated cannabinoid CB1 receptor binding in men with alcohol dependence.
    Neumeister A; Normandin MD; Murrough JW; Henry S; Bailey CR; Luckenbaugh DA; Tuit K; Zheng MQ; Galatzer-Levy IR; Sinha R; Carson RE; Potenza MN; Huang Y
    Alcohol Clin Exp Res; 2012 Dec; 36(12):2104-9. PubMed ID: 22551199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Type-1 cannabinoid receptor activity during Alzheimer's disease progression.
    Manuel I; González de San Román E; Giralt MT; Ferrer I; Rodríguez-Puertas R
    J Alzheimers Dis; 2014; 42(3):761-6. PubMed ID: 24946872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain.
    Hampel H; Haslinger A; Scheloske M; Padberg F; Fischer P; Unger J; Teipel SJ; Neumann M; Rosenberg C; Oshida R; Hulette C; Pongratz D; Ewers M; Kretzschmar HA; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2005 Aug; 255(4):269-78. PubMed ID: 15565298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Upregulation of Cortical A2A Adenosine Receptors Is Reflected in Platelets of Patients with Alzheimer's Disease.
    Merighi S; Battistello E; Casetta I; Gragnaniello D; Poloni TE; Medici V; Cirrincione A; Varani K; Vincenzi F; Borea PA; Gessi S
    J Alzheimers Dis; 2021; 80(3):1105-1117. PubMed ID: 33646165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Substance P-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex.
    Beal MF; Mazurek MF
    Neurology; 1987 Jul; 37(7):1205-9. PubMed ID: 2439949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [¹²⁵I]SD-7015 reveals fine modalities of CB₁ cannabinoid receptor density in the prefrontal cortex during progression of Alzheimer's disease.
    Farkas S; Nagy K; Palkovits M; Kovács GG; Jia Z; Donohue S; Pike V; Halldin C; Máthé D; Harkany T; Gulyás B; Csiba L
    Neurochem Int; 2012 Feb; 60(3):286-91. PubMed ID: 22222721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia.
    Deng C; Han M; Huang XF
    Neurosci Bull; 2007 Nov; 23(6):341-7. PubMed ID: 18064064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective loss of P2Y2 nucleotide receptor immunoreactivity is associated with Alzheimer's disease neuropathology.
    Lai MK; Tan MG; Kirvell S; Hobbs C; Lee J; Esiri MM; Chen CP; Francis PT
    J Neural Transm (Vienna); 2008 Aug; 115(8):1165-72. PubMed ID: 18506388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo.
    Van Laere K; Casteels C; Dhollander I; Goffin K; Grachev I; Bormans G; Vandenberghe W
    J Nucl Med; 2010 Sep; 51(9):1413-7. PubMed ID: 20720046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 5-HT
    Solas M; Van Dam D; Janssens J; Ocariz U; Vermeiren Y; De Deyn PP; Ramirez MJ
    Neurochem Int; 2021 Nov; 150():105185. PubMed ID: 34555475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cognition may link cortical IGFBP5 levels with motor function in older adults.
    Buchman AS; Yu L; Petyuk VA; Gaiteri C; Tasaki S; Blizinsky KD; Schneider JA; De Jager PL; Bennett DA
    PLoS One; 2019; 14(8):e0220968. PubMed ID: 31404102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients.
    Solas M; Francis PT; Franco R; Ramirez MJ
    Neurobiol Aging; 2013 Mar; 34(3):805-8. PubMed ID: 22763024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Altered expression of the CB1 cannabinoid receptor in the triple transgenic mouse model of Alzheimer's disease.
    Bedse G; Romano A; Cianci S; Lavecchia AM; Lorenzo P; Elphick MR; Laferla FM; Vendemiale G; Grillo C; Altieri F; Cassano T; Gaetani S
    J Alzheimers Dis; 2014; 40(3):701-12. PubMed ID: 24496074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cannabinoids and schizophrenia: therapeutic prospects.
    Robson PJ; Guy GW; Di Marzo V
    Curr Pharm Des; 2014; 20(13):2194-204. PubMed ID: 23829368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.
    Serpell MG; Notcutt W; Collin C
    J Neurol; 2013 Jan; 260(1):285-95. PubMed ID: 22878432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.
    Podda G; Constantinescu CS
    Expert Opin Biol Ther; 2012 Nov; 12(11):1517-31. PubMed ID: 22954177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.